We’re delighted to report the successful completion of our research project in Dr Yung-Yao Lin’s laboratory at Queen Mary University of London. The …
Project that aimed to combine stem cell and CRISPR technology is a successRead More
October 28, 2021 by Neil
We’re delighted to report the successful completion of our research project in Dr Yung-Yao Lin’s laboratory at Queen Mary University of London. The …
Project that aimed to combine stem cell and CRISPR technology is a successRead More
December 16, 2019 by Neil
Sarepta Therapeutics has announced that the FDA (the medicines regular in the US) has granted accelerated approval to golodirsen. Golodirsen, or …
December 9, 2019 by Neil
The UNITE-DMD project, which we are co-funding alongside Muscular Dystrophy UK and AFM-Téléthon brings together several strands of research to …
December 5, 2019 by Lynnette
We've welcomed over 100 people to our Science on Tour events throughout 2019, these empowering and invaluable sessions have been a huge success and we …
November 8, 2019 by Lynnette
Wow, we've had a busy few weeks here at AD HQ, delivering one of our 3 key objectives of 'building a community'. Our team have barely touched the …
December 14, 2018 by abzali123
Gene therapy for Duchenne muscular dystrophy aims to compensate for the lack of dystrophin by transferring a working version of the dystrophin gene …
June 27, 2018 by abzali123
Earlier today Summit Therapeutics announced the results of the PhaseOut DMD clinical trial of Ezutromid. Although Ezutromid was safe and well …
Summit announces results of PhaseOut DMD clinical trial of EzutromidRead More
June 5, 2018 by abzali123
SuAzio are currently conducting a study and are looking for individuals who live with Duchenne, or their caregivers to be part of this study. …
April 4, 2018 by abzali123
The Ulster University have approached Action Duchenne and our wonderful community to take part in an important research study which could benefit the …
Give your valuable experiences of caring and supporting a young person with DuchenneRead More
January 26, 2018 by abzali123
We are delighted to announce that the revised Standards of Care for Duchenne were published in The Lancet Neurology this week; a high-impact …
Revised Standards of Care for Duchenne muscular dystrophyRead More
January 25, 2018 by abzali123
Action Duchenne, a leading UK-wide patient and parent-led organisation for Duchenne Muscular Dystrophy, is delighted to announce the publication of a …
September 9, 2016 by abzali123
ReveraGen BioPharma have begun enrolment in the Phase 2a clinical trial of vamoroleone in the treatment of young people living with Duchenne muscular …
RevaraGen starts enrolment for steroid alternative clinical trialRead More
Action Duchenne
Wellesley House
Duke of Wellington Avenue Royal Arsenal
London
SE18 6SS
07535 498 506
info@actionduchenne.org